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Abstract
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, 
combined with bortezomib and dexamethasone in patients with relapsed or relapsed/
refractory multiple myeloma who had received 1-3 prior therapies.
Methods: This was a phase 2, single-arm, open-label, multicentre study (NCT02902965). 
The primary endpoint was progression-free survival (PFS).
Results: Seventy-six patients were enrolled; 74 received ≥1 dose of study treat-
ment. After median follow-up of 19.6 months, median PFS was 8.5 months (95% CI: 
6.2-10.8); median overall survival was not reached. Overall response rate was 57% 
(95% CI: 45-68), and median duration of response was 9.5 months (95% CI: 6.9-10.6). 
Grade 3/4 AEs occurred in 73% of patients and fatal AEs occurred in 15% of patients. 
Incidence of major haemorrhage was 5%; one patient died from cerebral haemor-
rhage. After an observed increased incidence of serious (42%) and fatal (11%) in-
fections, enrolment was suspended to implement risk-minimisation measures. The 
safety profile was otherwise consistent with known safety profiles of the individual 
drugs.
Conclusion: Ibrutinib combined with bortezomib and dexamethasone elicited clinical 
responses. However, efficacy assessments conducted at potential restart of enrol-
ment indicated that the targeted PFS could not be reached with additional patient 
enrolment, and the study was terminated.
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1  | INTRODUC TION
Multiple myeloma (MM) is a malignancy of terminally differenti-
ated plasma cells and is the second most common haematological 
malignancy after non-Hodgkin's lymphoma.1,2 Although novel drug 
combinations have improved outcomes for patients with MM, most 
patients will eventually relapse after initial treatment and the effi-
cacy of salvage regimens declines with each subsequent relapse.1 
Treatment choices in the relapsed setting are influenced by various 
factors, such as age, performance status, comorbidities, and/or ef-
ficacy and toxicity of previous treatments; the optimal treatment 
remains uncertain and an area of unmet clinical need.3 Current treat-
ment strategies involve the use of multiple agents that target specific 
signalling pathways involved in tumour cell growth and survival.
Bruton's tyrosine kinase (BTK) is overexpressed on MM tumour 
cells relative to normal plasma cells and has been implicated in the 
growth and survival of MM tumour cells.4,5 Overexpression of BTK 
in side population cells may contribute to the development of drug 
resistance in MM tumour cells.5 In particular, BTK-overexpressing 
cells demonstrated increased activity of the ATP-binding cassette 
(ABC) transporter efflux pump and increased expression of the 
ABCB1 transporter protein, thereby promoting resistance to bor-
tezomib, doxorubicin, and etoposide.5 Inhibition of the drug efflux 
pump was able to restore sensitivity to bortezomib.5
Ibrutinib, a first-in-class, once-daily oral inhibitor of BTK, is ap-
proved in the United States and European Union for the treatment of 
various B-cell malignancies.6,7 Ibrutinib has been shown to suppress 
tumour growth and improve MM-induced bone lysis in a murine 
model4 and has demonstrated in vitro cytotoxicity and synergy with 
bortezomib and lenalidomide in malignant plasma cells from patients 
with MM.8 In patients with relapsed/refractory (R/R) MM, ibrutinib 
demonstrated encouraging activity in combination with dexameth-
asone9 and in combination with carfilzomib plus dexamethasone,10 
warranting further investigation of ibrutinib with steroids and prote-
asome inhibitors. Bortezomib, in combination with dexamethasone, 
is currently approved for the treatment of R/RMM.11,12
This study was designed to assess the efficacy, safety, and toler-
ability of the addition of ibrutinib to the established treatment reg-
imen of bortezomib and dexamethasone in patients with relapsed 
or R/R MM.
2  | METHODS
2.1 | Study design and patients
PCYC-1139 (ClinicalTrials.gov identifier, NCT02902965) was a 
non-randomised, open-label, international, multicentre, sponsor-
initiated, phase 2 study conducted at multiple sites in Europe. 
Eligible patients were aged ≥18 years with a diagnosis of active 
MM per International Myeloma Working Group (IMWG) criteria,13 
had received one to three prior lines of therapy, and had demon-
strated progressive disease (PD) since completion of their most 
recent treatment regimen. Patients could have received prior 
bortezomib treatment but must not have been refractory or non-
responsive to bortezomib treatment. All patients were required to 
have measurable disease, defined as at least one of the following: 
serum monoclonal protein (SPEP) ≥1 g/dL (for patients with im-
munoglobulin [Ig] A, IgD, IgE, or IgM MM SPEP ≥0.5 g/dL) or urine 
monoclonal protein ≥200 mg by 24-hour urine electrophoresis. 
Additional inclusion criteria were Eastern Cooperative Oncology 
Group performance status ≤2 and adequate haematological (ab-
solute neutrophil count ≥1.5 × 109/L; platelet count ≥75 × 109/L), 
hepatic, and renal function. Patients were excluded if they had 
primary refractory disease (defined as failure to achieve a mini-
mal response or better with any therapy); had disease refractory 
Novelty statements
• What is the new aspect of your work?
• This study evaluated the novel combination of ibruti-
nib, a once-daily oral inhibitor of Bruton's tyrosine ki-
nase, with bortezomib plus dexamethasone in patients 
with relapsed/refractory multiple myeloma. Bruton's 
tyrosine kinase is overexpressed on multiple myeloma 
cells and may contribute to development of drug re-
sistance. Ibrutinib has demonstrated in vitro synergy 
with bortezomib and encouraging activity in combina-
tion with dexamethasone and carfilzomib plus dexa-
methasone in phase 1 and 2 studies in patients with 
relapsed/refractory multiple myeloma.
• What is the central finding of your work?
• Ibrutinib in combination with bortezomib and dexa-
methasone elicited clinical responses. However, the 
study was closed early after efficacy assessments 
indicated that the targeted median progression-free 
survival of >12 months could not be reached with the 
enrolment of additional patients.
• What is (or could be) the specific clinical relevance of 
your work?
• The optimal treatment for multiple myeloma in the 
relapsed/refractory setting remains uncertain and an 
area of unmet clinical need. Despite strong ration-
ale based on preclinical and early clinical studies, the 
combination of ibrutinib with bortezomib and dexa-
methasone did not demonstrate sufficient activity to 
warrant further study in patients with relapsed/refrac-
tory multiple myeloma. Clinical studies evaluating the 
safety and efficacy of novel combinations are critical 
to identifying more effective salvage treatment op-
tions for patients with multiple myeloma. The informa-
tion gained from these studies of novel combinations, 
regardless of the outcome, can help to inform future 
studies seeking to address this unmet clinical need.
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(defined as progression on treatment or within 60 days of com-
pletion) or non-responsive (defined as failure to achieve minimal 
response or better) to prior proteasome inhibitor therapy; had a 
history of plasma cell leukaemia, primary amyloidosis, or POEMS 
(polyneuropathy, organomegaly, endocrinopathy, monoclonal 
gammopathy, skin abnormalities) syndrome within 12 months 
prior to first administration of study treatment; peripheral neu-
ropathy grade ≥2 or grade 1 with pain at screening; had currently 
active or clinically significant cardiovascular disease (uncontrolled 
arrhythmia or class III or IV congestive heart failure as defined 
by the New York Heart Association Functional Classification), or 
a history of myocardial infarction, unstable angina, or acute coro-
nary syndrome within 6 months prior to enrolment; had currently 
active, clinically significant hepatic impairment (mild impairment 
or worse by Child-Pugh classification); or required treatment with 
strong CYP3A inhibitors.
After 74 patients had initiated study treatment, study enrol-
ment was suspended because of an initially observed increase of 
serious and fatal infections. During the enrolment halt, enrolled 
patients continued to receive treatment with the immediate imple-
mentation of risk-minimisation measures, which included modifica-
tions to the dexamethasone dosing regimen that effectively halved 
the dose of dexamethasone in the triple combination (described in 
“Treatments” section below), and strengthened guidance for infec-
tion prophylaxis. A Safety Review Committee was also established 
to evaluate the rate of new infections every 6 weeks following im-
plementation of the risk-minimisation measures and enrolment was 
approved to restart approximately 6 months after the enrolment 
halt as a result of these risk-minimisation measures. However, an 
evaluation of the efficacy data performed at this time indicated that 
the primary endpoint was unlikely to be achieved. As a result, the 
study was terminated and enrolment was not restarted.
The study was conducted in accordance with International 
Conference on Harmonization guidelines for Good Clinical Practice 
and principles of the Declaration of Helsinki. The protocol and its 
amendments were approved by independent ethics committees of 
all participating institutions and all patients provided written in-
formed consent.
2.2 | Treatments
During cycles 1 to 8, patients received oral ibrutinib 840 mg once 
daily in combination with subcutaneous bortezomib 1.3 mg/m2 on 
days 1, 4, 8, and 11 and oral dexamethasone 20 mg on days 1, 2, 
4, 5, 8, 9, 11, and 12 of each 21-day cycle. With the implemen-
tation of risk-minimisation measures, dosing of dexamethasone 
was limited to days 1, 4, 8, and 11. During cycles 9 to 12, patients 
received ibrutinib 840 mg once daily in combination with bort-
ezomib 1.3 mg/m2 on days 1, 8, 22, and 29, and dexamethasone 
20 mg on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. 
With the implementation of risk-minimisation measures, dosing of 
dexamethasone was limited to days 1, 8, 22, and 29. From cycle 
13 onward, patients received ibrutinib 840 mg once daily in com-
bination with dexamethasone 40 mg once weekly in each 28-day 
cycle. For patients aged >75 years, adjustment of the dexametha-
sone dose to 10 mg was recommended for cycles 1 to 12, and 
adjustment to 20 mg was recommended for cycle 13 onward, at 
the discretion of the investigator. Treatment with ibrutinib plus 
dexamethasone was continued until PD, unacceptable toxicity, or 
other protocol-specified reason for discontinuation.
2.3 | Outcomes and assessments
Efficacy endpoints were assessed by investigators according to 
IMWG criteria.13 The primary efficacy endpoint was progression-
free survival (PFS), defined as the time from the first dose of study 
treatment to confirmed PD or death from any cause. Secondary 
endpoints were overall response rate (ORR), defined as partial re-
sponse or better; PFS rate at landmark time points; duration of 
response, defined as the time from initial documentation of re-
sponse to the first documented evidence of PD; overall survival 
(OS), defined as the time from the first dose of study treatment 
to death from any cause; time to progression, defined as the time 
from the first dose of study treatment until PD; and the safety 
and tolerability of ibrutinib in combination with bortezomib and 
dexamethasone. Pharmacokinetic characteristics of ibrutinib and 
bortezomib when given in combination with dexamethasone were 
assessed as an exploratory endpoint.
Response and progression were assessed per IMWG criteria13 
every 3 weeks during cycles 2 to 12 and every 4 weeks thereaf-
ter. In case of suspected complete response, pertinent assessments 
were performed per the IMWG response assessment guidelines. 
Following confirmed PD, patients were contacted approximately 
every 12 weeks for long-term survival follow-up. Plasma samples 
for analysis of ibrutinib and bortezomib pharmacokinetics were col-
lected predose and at 30 minutes; 1, 2, 4, and 6 hours postdose on 
day 1 of cycle 2; and predose on day 2 of cycle 2.
Safety assessments included adverse events (AEs), laboratory 
evaluations, physical examinations, and vital signs. Adverse events 
were monitored throughout treatment until 30 days after the last dose 
of study treatment. Adverse events were coded by preferred term 
using the Medical Dictionary for Regulatory Activities (MedDRA), 
version 21.1, and were graded according to National Cancer Institute 
Common Terminology Criteria for Adverse Events, version 4.03.
2.4 | Statistical analysis
Efficacy and safety were evaluated in all patients who received at 
least one dose of study treatment. Time-to-event endpoints were 
estimated using the Kaplan-Meier method. For PFS, two-sided 95% 
confidence intervals (CIs) were calculated using the Brookmeyer-
Crowley method with the log-log transformed Greenwood variance 
estimate to test the null hypothesis. For ORR, two-sided 95% CIs were 
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calculated using the exact binomial method. Pharmacokinetics were 
analysed by non-compartmental methods using Phoenix WinNonlin 
(Certara USA Inc), and AEs were summarised descriptively.
A sample size of approximately 125 patients was required to 
achieve 80% power at a one-sided 0.025 significance level to test the 
null hypothesis of median PFS ≤8 months versus ≥12 months under 
the alternative hypothesis, with the assumption that the PFS follows 
an exponential distribution. However, a review of the available ef-
ficacy data at the time of potential restart of enrolment indicated 
that the primary endpoint was unlikely to be achieved; therefore, 
hypothesis testing for PFS was not performed.
2.5 | Data sharing statement
Requests for access to individual participant data from clinical stud-
ies conducted by Pharmacyclics LLC, an AbbVie Company, can be 




A total of 76 patients were enrolled, and 74 patients received 
at least one dose of study treatment (Table 1). Median age was 
67.5 years and 61% were aged ≥65 years (Table 2). All patients had 
received prior systemic therapy for MM; 61% of patients had re-
ceived one line of therapy and 39% had received two or three lines 
of therapy. The most common prior systemic therapies (reported in 
≥30% of patients) were dexamethasone (88%), bortezomib (81%), 
cyclophosphamide (65%), lenalidomide (39%), and melphalan 
(31%). Overall, 39% of all patients were refractory to the last line of 
therapy. At the time of final analysis, all patients had discontinued 
study treatment; the most common reasons for discontinuation 
were PD (50%), AEs (18%), and patient withdrawal (14%) (Table 1). 
The median follow-up duration was 19.6 months (range, 0.2-24.6).
3.2 | Safety
The median duration of treatment was 5.7 months (range, 0.1-
23.7) for ibrutinib, 4.5 months (range, 0.0-12.6) for bortezomib, 
TA B L E  1   Patient disposition
 Patients
Enrolled, n 76
Did not receive treatment, n 2
Started treatment, n 74
Discontinued treatment, n (%) 74 (100)
Progressive disease 37 (50)
Adverse event 13 (18)
Withdrawal by patient 10 (14)
Death 7 (9)
Physician decision 4 (5)
Study termination by sponsor 3 (4)





Median, years (range) 67.5 (37-86)
≥65 y, n (%) 45 (61)
Male sex, n (%) 35 (47)
White race, n (%) 71 (96)




Median time since diagnosis, years (range) 4.2 (0.4-13.7)




Measurable disease, n (%)  
UPEP only 6 (8)
SFLC only 0
SPEP only 42 (57)
SPEP and UPEP 26 (35)






Median bone marrow plasma cell percentage 
(range)
23 (2-99)
Number of prior lines of therapy, n (%)  
1 45 (61)
2-3 29 (39)
Previous transplantation, n (%) 43 (58)






Refractory to last line of therapy, n (%) 29 (39)
Note: Abbreviations: ANC, absolute neutrophil count; ECOG PS, Eastern 
Cooperative Oncology Group performance status; ISS, International 
Staging System; SFLC, serum-free light-chain assay; SPEP, serum 
monoclonal protein; UPEP, urine monoclonal protein.
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and 5.6 months (range, 0.1-20.1) for dexamethasone. The most 
common AEs of any grade were thrombocytopenia (61% of pa-
tients), diarrhoea (55%), anaemia (38%), asthenia (30%), fatigue 
(28%), peripheral oedema (28%), upper respiratory tract infection 
(26%), nausea (24%), peripheral sensory neuropathy (24%), cough 
(20%), and back pain (20%) (Table 3). Grade 3/4 AEs were reported 
in 73% of patients, and fatal AEs were reported in 15% of patients. 
The most common grade 3 or higher AEs (occurring in ≥10% of pa-
tients) were thrombocytopenia (34%), pneumonia (16%), anaemia 
(15%), and asthenia (14%). Serious AEs of any grade occurred in 47 
patients (64%). The only serious AE occurring in ≥5% of patients 
was pneumonia, which occurred in 11 patients (15%); serious AEs 
of pneumonia were grade 3/4 in nine patients (12%), and grade 5 
in two patients (3%).
Infections were reported in 59 patients (80%) and were grade 3 or 
higher in 32 patients (43%); the most common infections of any grade 
(occurring in ≥10% of patients) were upper respiratory tract infection 
(26%), pneumonia (18%), bronchitis (15%), conjunctivitis (14%), naso-
pharyngitis (14%), and urinary tract infection (11%). Serious infections 
were reported in 31 patients (42%), with pneumonia being the most 
common serious infection (15%). Fatal infections were reported as AEs 
in eight patients (11%), coded as MedDRA-preferred terms of sepsis 
(n = 3) and pseudomonal sepsis (n = 1) for a total of four fatal infections 
due to sepsis; and pneumonia (n = 2), pneumonia Escherichia (n = 1), 
and pneumonia bacterial (n = 1) for a total of four fatal infections due 
to pneumonia. Additional fatal AEs were cerebral haemorrhage, death 
(unknown cause), and sudden death (n = 1 each).
Bleeding events of any grade were reported in 23 patients (31%). 
Major haemorrhage was reported in four patients (5%); one event (ce-
rebral haemorrhage) resulted in treatment discontinuation and was 
subsequently fatal. Atrial fibrillation occurred in seven patients (9%) 
and was grade 3/4 in three patients (4%). Adverse events leading to 
dose reduction of ibrutinib, bortezomib, and dexamethasone occurred 
in 38 (51%), 30 (41%), and 19 (26%) patients, respectively, and AEs lead-
ing to discontinuation of ibrutinib, bortezomib, and dexamethasone oc-
curred in 18 (24%), 22 (30%), and 20 (27%) patients, respectively. The 
most common AEs leading to ibrutinib discontinuation were pneumo-
nia (n = 3; 4%), atrial fibrillation, diarrhoea, and sepsis (n = 2 each; 3%). 
The most common AEs leading to bortezomib discontinuation were 
polyneuropathy (n = 3; 4%), atrial fibrillation, diarrhoea, peripheral 
sensorimotor neuropathy, pneumonia, and sepsis (n = 2 each; 3%). The 
most common AEs leading to discontinuation of dexamethasone were 
atrial fibrillation, diarrhoea, pneumonia, and sepsis (n = 2 each; 3%).
3.3 | Efficacy
After a median follow-up of 19.6 months, PFS events had occurred 
in 55 patients (74%). The median PFS was 8.5 months (95% CI: 6.2-
10.8) and estimated PFS at 20 months was 7% (Figure 1A).
The ORR was 57% (95% CI: 45-68), including complete response 
in one patient, very good partial response in 13 patients, and partial 
response in 28 patients (Table 4). Among 42 patients who achieved 
partial response or better, the median duration of response was 
9.5 months (95% CI: 6.9-10.6) and the median time to progression 
was 10.6 months (95% CI: 7.8-12.0). At the time of analysis, 27 pa-
tients (36%) had died and median OS was not reached (Figure 1B). 
Estimated OS at 24 months was 54%.
3.4 | Pharmacokinetics
Steady-state plasma exposures of ibrutinib at the 840 mg dose level 
in this study were similar to those observed in patients with R/R 
MM receiving ibrutinib in combination with carfilzomib in the PCYC-
1119-CA study.10 Steady-state plasma exposures of bortezomib 
were consistent with those reported in the US prescribing informa-
tion for bortezomib.14
4  | DISCUSSION
This phase 2 study evaluated the efficacy and safety of ibrutinib in 
combination with bortezomib plus dexamethasone in patients with 
R/R MM who had received one to three previous lines of therapy. 
After 74 patients had received at least one dose of study treatment, 
study enrolment was suspended as a risk-minimisation measure to ad-
dress concerns over an increased incidence of serious and fatal infec-
tions compared with other studies of ibrutinib in R/R MM.9,10 While 
the incidence of infection of any grade in this study (80%) was similar 
TA B L E  3   Adverse events of any grade occurring in ≥15% of 
patients
Adverse event, n (%)
Patients (N = 74)
Any Grade Grade 3/4 Grade 5
Any adverse event 74 (100) 54 (73) 11 (15)
Thrombocytopenia 45 (61) 25 (34) 0
Diarrhoea 41 (55) 7 (9) 0
Anaemia 28 (38) 11 (15) 0
Asthenia 22 (30) 10 (14) 0
Fatigue 21 (28) 6 (8) 0
Oedema peripheral 21 (28) 0 0
Upper respiratory 
tract infection
19 (26) 2 (3) 0
Nausea 18 (24) 1 (1) 0
Peripheral sensory 
neuropathy
18 (24) 1 (1) 0
Back pain 15 (20) 2 (3) 0
Cough 15 (20) 0 0
Hypokalaemia 13 (18) 3 (4) 0
Pneumonia 13 (18) 10 (14) 2 (3)a
Pyrexia 13 (18) 0 0
aDoes not include two additional grade 5 AEs of pneumonia reported as 
pneumonia escherichia and pneumonia bacterial (n = 1 each). 
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to rates reported with ibrutinib in other haematological malignancies 
(68%-78%) over median follow-up durations of 9.4 to 33.4 months, 
the incidence of grade ≥3 infections (43%) was higher than rates pre-
viously reported with ibrutinib (7%-29%).15-20 However, it should be 
noted that a higher dose of ibrutinib (840 mg once daily) was used in 
the current study compared with other haematological malignancies 
(420 mg or 560 mg once daily). The ibrutinib dose used in the current 
study was chosen based on clinical activity and a favourable safety 
profile observed at the 840 mg dose level of ibrutinib in combination 
with carfilzomib with or without dexamethasone and in combination 
with dexamethasone in two early phase studies in MM.9,10 Plasma ex-
posures to ibrutinib and bortezomib were consistent with those pre-
viously reported,10,14 suggesting that drug-drug interactions may not 
be contributing factors to the safety observations. Relative to other 
studies conducted in patients with MM, the incidence of grade ≥3 
AEs observed with ibrutinib plus bortezomib and dexamethasone in 
the current study (88%) was similar to the incidence observed with 
ibrutinib plus carfilzomib with or without dexamethasone (86%),10 but 
higher than that observed with ibrutinib alone or in combination with 
dexamethasone without a proteasome inhibitor (57%).9
A review of the data after the implementation of risk-minimisa-
tion measures showed a lower rate of serious infections and no fatal 
infections among patients already enrolled in the study. However, 
validation of the effectiveness of the risk-minimisation measures was 
not possible as no new patients were enrolled. Apart from infections, 
the safety profile was consistent with the known safety profiles of 
the individual study drugs.6,7,11,12 While safety profiles in general 
may vary depending on dosage, combination with other drugs, and 
by disease histology, incidences of AEs of interest with ibrutinib 
were largely consistent with previous reports across a range of hae-
matological malignancies, including chronic lymphocytic leukaemia, 
Waldenström’s macroglobulinemia, and mantle cell lymphoma.15-20 
The median PFS of 8.5 months with ibrutinib plus bortezomib and 
dexamethasone was slightly longer than that observed in patients 
with R/R MM treated with placebo plus bortezomib and dexameth-
asone in the PANORAMA-1 study (median 8.1 months).21 Such indi-
rect comparisons should, however, be interpreted with caution given 
differences in study design. Clinical response was observed in 57% 
of patients and was generally durable, with a median response dura-
tion of 9.5 months. Overall survival data were not yet mature, with 
64% of patients remaining alive after a median follow-up duration of 
19.6 months. Assessment of efficacy at the time of potential restart 
of enrolment indicated that the target median PFS for the alternative 
hypothesis (≥12 months) could not be reached by enrolling additional 
patients, and therefore, enrolment was not restarted. Because en-
rolment was suspended due to safety concerns before the target 
sample size had been reached, the hypothesis testing for the median 
PFS was not performed.
F I G U R E  1   Kaplan-Meier estimates 
of (A) PFS per investigator assessment 
and (B) OS. NE, not estimable; NR, 
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In summary, an initially increased incidence of serious infections 
was observed with ibrutinib in combination with bortezomib and 
dexamethasone, and in response, risk-minimisation measures were 
introduced. Following the implementation of risk-minimisation mea-
sures, very few serious and no fatal infections occurred, and reg-
ulatory authorities and ethics committees approved the restart of 
enrolment. Ibrutinib in combination with bortezomib and dexameth-
asone elicited clinical responses in patients with R/R MM. However, 
an efficacy assessment at the time of the potential restart of enrol-
ment indicated that even with the pending enrolment of additional 
patients, the targeted endpoint of median PFS could not be reached 
and the study was terminated.
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